Sovaldi Side Effects

Generic Name: sofosbuvir

Note: This page contains side effects data for the generic drug sofosbuvir. It is possible that some of the dosage forms included below may not apply to the brand name Sovaldi.

It is possible that some side effects of Sovaldi may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

For the Consumer

Applies to sofosbuvir: oral tablet

As well as its needed effects, sofosbuvir (the active ingredient contained in Sovaldi) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking sofosbuvir, check with your doctor immediately:

More common
  • chills
  • fever
  • lower back or side pain
  • pale skin
  • ulcers, sores, or white spots in the mouth
  • unusual tiredness or weakness
Rare
  • Changes in behavior
  • discouragement
  • feeling sad or empty
  • loss of interest or pleasure
  • thoughts of killing oneself
  • trouble concentrating

Some sofosbuvir side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common
  • Decreased appetite
  • diarrhea
  • difficulty with moving
  • fatigue
  • headache
  • irritability
  • lack or loss of strength
  • muscle aching or cramping
  • muscle pains or stiffness
  • nausea
  • rash or itching skin
  • trouble sleeping

For Healthcare Professionals

Applies to sofosbuvir: oral tablet

General

Sofosbuvir should be used with ribavirin or peginterferon/ribavirin. The prescribing information for these agents should be consulted for side effects.

The most common side effects reported with sofosbuvir (the active ingredient contained in Sovaldi) and ribavirin therapy were fatigue and headache. The most common side effects reported with sofosbuvir, peginterferon, and ribavirin therapy were fatigue, headache, nausea, insomnia, and anemia. Therapy was permanently discontinued due to side effects in 4% of subjects using placebo, 1% of subjects using sofosbuvir and ribavirin for 12 weeks, less than 1% of subjects using sofosbuvir and ribavirin for 24 weeks, 11% of subjects using peginterferon alfa and ribavirin for 24 weeks, and 2% of subjects using sofosbuvir, peginterferon alfa, and ribavirin for 12 weeks.

Other

Very common (10% or more): Fatigue (up to 59%), asthenia (up to 21%), pyrexia (up to 18%), chills (up to 17%), influenza-like illness (up to 16%)

Nervous system

Very common (10% or more): Headache (up to 36%)

Gastrointestinal

Lipase elevation was isolated and asymptomatic.

Very common (10% or more): Nausea (up to 34%), diarrhea (up to 12%)
Common (1% to 10%): Increased lipase (greater than 3 times upper limit of normal [ULN]: up to 2%)

Dermatologic

Very common (10% or more): Pruritus (up to 27%), rash (18%)

Psychiatric

Very common (10% or more): Insomnia (up to 25%), irritability (up to 13%)
Uncommon (0.1% to 1%): Severe depression (including suicidal ideation, suicide; less than 1%)

Severe depression was reported, particularly in patients with history of psychiatric illness.

Hematologic

Very common (10% or more): Decreased hemoglobin (less than 10 g/dL: up to 23%), anemia (up to 21%), neutropenia (up to 17%), decreased neutrophils (0.5 to less than 0.75 x 10[9]/L: up to 15%)
Common (1% to 10%): Decreased neutrophils (less than 0.5 x 10[9]/L: up to 5%), decreased hemoglobin (less than 8.5 g/dL: up to 2%)
Uncommon (0.1% to 1%): Decreased platelets (25 to less than 50 x 10[9]/L: up to 1%), pancytopenia (less than 1%)

Pancytopenia was reported, particularly in patients using concomitant pegylated interferon.

Metabolic

Very common (10% or more): Decreased appetite (up to 18%)

Musculoskeletal

Creatine kinase elevation was isolated and asymptomatic.

Very common (10% or more): Myalgia (up to 14%)
Common (1% to 10%): Increased creatine kinase (at least 10 times ULN: up to 2%)

Hepatic

Common (1% to 10%): Increased total bilirubin (greater than 1.5 times ULN: up to 3%)

Bilirubin levels peaked during the first 1 to 2 weeks of therapy then decreased and returned to baseline levels by 4 weeks after therapy. These bilirubin elevations were not associated with transaminase elevations.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web3)